ArticleViruses2021
The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City.
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Pooled it
- Article
- A panoramic view of hospitalized young children in the metropolitan area of the valley of Mexico during COVID-19.IJID regions · 2023Article
- Some common deleterious mutations are shared in SARS-CoV-2 genomes from deceased COVID-19 patients across continents.Scientific reports · 2023Article
- SARS-CoV-2 Variants of Concern and Clinical Severity in the Mexican Pediatric Population.Infectious disease reports · 2023Article
- Genome analysis of SARS-CoV-2 isolates from a population reveals the rapid selective sweep of a haplotype carrying many pre-existing and new mutations.Virology journal · 2023Article
- Comparing the evolutionary dynamics of predominant SARS-CoV-2 virus lineages co-circulating in Mexico.eLife · 2023Article
- Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.NPJ vaccines · 2023Article
- Sex, Age, and Comorbidities Are Associated with SARS-CoV-2 Infection, COVID-19 Severity, and Fatal Outcome in a Mexican Population: A Retrospective Multi-Hospital Study.Journal of clinical medicine · 2023Article
- Temporal dynamics and fatality of SARS-CoV-2 variants in Bangladesh.Health science reports · 2023Article
- Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Molecular transition of SARS-CoV-2 from critical patients during the first year of the COVID-19 pandemic in Mexico City.Frontiers in cellular and infection microbiology · 2023Article
- COVID-19 reinfections in Mexico City: implications for public health.Frontiers in public health · 2023Article
- Exploring disparities and novel insights into metabolic and cardiovascular comorbidities among COVID-19 patients in Mexico.Frontiers in public health · 2023Observational
- Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.Frontiers in public health · 2023Article
- Longitudinal clinical phenotyping of post COVID condition in Mexican adults recovering from severe COVID-19: a prospective cohort study.Frontiers in medicine · 2023Article
- Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes.Vaccines · 2022Article
- Pattern of SARS-CoV-2 variant B.1.1.519 emergence in Alaska.Scientific reports · 2022Article
- Probability of hospitalisation and death among COVID-19 patients with comorbidity during outbreaks occurring in Mexico City.Journal of global health · 2022Article
- Clinical and Virological Features of Patients Hospitalized with Different Types of COVID-19 Vaccination in Mexico City.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 1 country.
Funding
Abstract
The SARS-CoV-2 pandemic is one of the most concerning health problems around the globe. We reported the emergence of SARS-CoV-2 variant B.1.1.519 in Mexico City. We reported the effective reproduction number (Rt) of B.1.1.519 and presented evidence of its geographical origin based on phylogenetic analysis. We also studied its evolution via haplotype analysis and identified the most recurrent haplotypes. Finally, we studied the clinical impact of B.1.1.519. The B.1.1.519 variant was predominant between November 2020 and May 2021, reaching 90% of all cases sequenced in February 2021. It is characterized by three amino acid changes in the spike protein: T478K, P681H, and T732A. Its Rt varies between 0.5 and 2.9. Its geographical origin remain to be investigated. Patients infected with variant B.1.1.519 showed a highly significant adjusted odds ratio (aOR) increase of 1.85 over non-B.1.1.519 patients for developing a severe/critical outcome (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.